Navigation Links
Biostar Pharmaceuticals Approved for Listing on NASDAQ Global Market
Date:4/22/2010

XIANYANG, China, April 22 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM) ("Biostar" or "the Company"), a Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules ("Xin Aoxing"), and a variety of pharmaceutical products, today announced that the Company was approved by NASDAQ to list its common stock on the NASDAQ Global Market. The Company's listing application was reviewed and approved by NASDAQ's Listing Qualifications Department for compliance with all of NASDAQ's standards.

The Company's common stock will commence trading on the NASDAQ Global Market under the ticker symbol BSPM on April 23, 2010.

Announcing the listing, Chairman Mr. Ronghua Wang said, "Given Biostar's continued success and ongoing opportunities, we feel the time is right to increase our exposure to the financial markets. We believe moving to the NASDAQ Global Market will benefit our investors and is the next logical step in the Company's future growth."

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary in China, develops, manufactures and markets pharmaceutical products for a variety of diseases and conditions. The Company's most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. In addition to its hepatitis product, Biostar manufactures two broad-based OTC products and two prescription-based pharmaceuticals. The Company has adopted international standards, holds one paten
'/>"/>

SOURCE Biostar Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results
2. Biostar Pharmaceuticals, Inc. Receives the Chinese Military Drug Administration Clearance to Begin Clinical Trial for Zushima Analgesic Aerosol Spray
3. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
4. Renhuang Pharmaceuticals Announces Continual Improvement in Days Sales Outstanding
5. Celator(R) Pharmaceuticals Presents New Data on Two Nano-Scale Delivery Platforms at the American Association for Cancer Research
6. Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
7. Isis Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference
8. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
9. Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
10. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
11. Poniard Pharmaceuticals Announces $6.3 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... Aug. 3, 2015  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... TELESTAR Phase 3 clinical trial met its primary ... in treating cancer patients with carcinoid syndrome that ... of care. Telotristat etiprate was discovered using Lexicon,s ... is the company,s first discovery to complete a ...
(Date:7/31/2015)... -- Seeger Weiss LLP is reporting that on July 13, 2015, ... C.R. Bard, the manufacturer of Inferior vena cava (IVC) ... the agency found at two of Bard,s facilities. Bard was ... them during Inspectional Observations that occurred on November 18, 2014, ... , location and on October 6, 2014, through November ...
(Date:7/31/2015)... 31, 2015 RnRMarketResearch.com adds ... research report that provides an overview of syringes ... sourced from in-house databases, secondary and primary research. ... market products pipeline spread across 124 pages, talking ... tables and 5 figures is now available at ...
Breaking Medicine Technology:Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
... Pa., Dec. 7, 2011  Inovio Pharmaceuticals, Inc. (NYSE Amex: ... to fight cancers and infectious diseases, announced today that ... shares of its common stock and warrants to purchase ... which included the partial exercise of the underwriter,s overallotment ...
... -- The November 14, 2011, edition of ... Presence (VIP) as 4 stars ("would take it on ... Experiment (AEWE),s Spiral G at Fort Benning, GA, culminating ... and November 2011.  "It was a pleasure ...
Cached Medicine Technology:Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing 2Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing 3Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing 4VIPAAR's VIP Earns 4-star Technology Rating at AEWE's Spiral G 2
(Date:8/3/2015)... ... August 03, 2015 , ... The Workgroup for Electronic Data Interchange ( WEDI ... efficiencies in healthcare information exchange, announced the release of its findings from its June ... (HHS) Secretary, WEDI shared survey results and recommendations , strongly encouraging ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to pay ... claims in which a claimant alleged to have suffered an arterial blood clot including ... control pills, Yaz, Yasmin and Ocella, has been ongoing for well-over five years. In ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... to contract research organisations (CROs) for a slew of benefits, allowing them to ... and operations, boost quality with cost-effective utilisation of resources, get access to innovation ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bodybuilding.com, ... of nutritional supplements, has officially opened the polls for their eleventh annual ... following categories:, ,     Brand of the Year (BPI Sports) ...
(Date:8/3/2015)... ... August 03, 2015 , ... The art of preparing ... from her grandmother’s side at a young age, Nasreen Zereshki was extremely eager to ... to share her cookbook Recipes from My Persian Kitchen with the world. , Since ...
Breaking Medicine News(10 mins):Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2
... South Korea, July 20 HepaHope Korea ... owned subsidiary, VASKA, a Berkeley-based producer of green, botanically-based ... successfully turned the first major commercial laundry plant in the United ... South San Francisco is the largest privately owned commercial laundry on ...
... , CARY, N.C., July 20 ... company focused on acquiring, developing and commercializing products primarily for ... Executive Vice President, Finance, and Chief Financial Officer, has been ... in the Small Public Business category. Award recipients were ...
... CARLSBAD, Calif., July 20 SynergEyes, Inc., ... a new advanced lens design for keratoconus patients. ClearKone(TM) ... the best features of the hybrid platform, providing superior ... design is optimized to vault the predominant irregularities of ...
... , BANNOCKBURN, Ill., July 20 Heart disease is ... it,s often not until the untimely passing of a celebrity from a ... the issue is brought to the forefront of Americans, health and wellness ... a recent survey(2) uncovered that only 14 percent of people would be ...
... Population older than 65 could reach 1.3 billion by 2040 ... people who are age 65 and older will double from ... 2040, says a new U.S. Census Bureau study. , The ... last year to 1.3 billion in 30 years. The unprecedented ...
... PLAINS, N.Y. and CAMBRIDGE, Mass., July 20 The ... partnership to accelerate LLS,s pipeline of research projects entering late pre-clinical ... will begin with a selection of ten small molecule candidates, discovered ... of advancing into clinical trials in the shortest period of time. ...
Cached Medicine News:Health News:HepaHope Korea Subsidiary VASKA Introduces Green Chemicals to U.S. Commercial Laundry Industry 2Health News:Cornerstone Therapeutics' David Price Named 2009 Chief Financial Officer of the Year by the Triangle Business Journal 2Health News:SynergEyes, Inc. Launches New Hybrid Lens Design for Keratoconus Patients 2Health News:SynergEyes, Inc. Launches New Hybrid Lens Design for Keratoconus Patients 3Health News:Need for At-Home Blood Pressure Monitoring Underscored by High-Profile Cardiac Deaths 2Health News:Need for At-Home Blood Pressure Monitoring Underscored by High-Profile Cardiac Deaths 3Health News:Elder Boom Will Be Felt Worldwide 2Health News:The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster 2Health News:The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster 3
Research® Series 2100 Adjustable-volume Pipette, 0.5-10 µl, single-channel with adjustable-volume setting...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,412-7) or contact custom...
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... features: Eppendorf "pipette/tip" system ensures utmost ...
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
Medicine Products: